Randomized trial · people
PT-141 with alcohol was well tolerated in 24 healthy adults
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this early safety study, single doses of bremelanotide taken with alcohol did not add safety problems or change how the body handled either one in healthy adults.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 24
- Published
- 2017
- Journal
- Clin Ther
What they tested
The team tested whether bremelanotide is safe and tolerable when taken together with alcohol, and whether alcohol changes how the body handles the drug.
How the study was done
A randomized, placebo-controlled, double-blind crossover trial (each person got several treatment combinations in turn) in 24 healthy adults, 12 men and 12 women, over 7 days at a research site. On days 1, 4 and 7 they got a single 20 mg nasal dose of bremelanotide or placebo (a dummy dose), with or without 0.6 g/kg of alcohol by mouth, while fasting.

What they found
All 24 people finished the study. The 20 mg nasal doses were judged safe and mostly well tolerated, with or without alcohol, and women reached average peak blood alcohol levels above 80 mg/dL. The team found no clinically significant pharmacokinetic interaction (no meaningful change in how the body handles either substance), overall or by sex, and no significant drug-related drops in blood pressure, including on standing. Bremelanotide did not raise the rate of side effects, no one dropped out because of side effects, and physical exams, ECGs (heart tracings) and lab tests showed no clinically significant changes.
What it doesn’t show
This was a small, short study of single doses in healthy volunteers, so it does not show what happens with repeated use or in people with health problems. It tested a nasal form, which the team said gives exposure about 1 to 2 times that of the injected dose being studied in phase III trials.
The paper
Clayton et al. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017.
The compound
More studies on PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: desire gains over placebo held across RECONNECT subgroupsRandomized trial · people · 2022
- PT-141: more responders than placebo at 1.75 mg on all 7 measuresRandomized trial · people · 2019
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.